206 findings · Metabolic adaptation · published 2025+
- Metabolic adaptationStrong
Prior GLP-1 agonist use is not associated with in-hospital mortality in critically ill patients.
Clinicians may consider that prior GLP-1 agonist use does not adversely affect mortality in critically ill patients.
Refutes 2025New - Metabolic adaptationStrong
Prior GLP-1 agonist use is not associated with hospital length of stay in critically ill patients.
Clinicians may conclude that prior GLP-1 agonist use does not prolong hospital stays for critically ill patients.
Refutes 2025New - Metabolic adaptationStrong
Prior GLP-1 agonist use is not associated with ICU length of stay in critically ill patients.
Clinicians may determine that prior GLP-1 agonist use does not affect ICU length of stay for critically ill patients.
Refutes 2025New - Metabolic adaptationStrong
Liraglutide did not have measurable effects on lean or bone tissue over the 18-day period.
Liraglutide may not affect muscle or bone mass in the short term.
Supports 2025New - Metabolic adaptationStrong
SGLT-2 inhibitors lower blood sugar independently of insulin, reduce heart failure risk, slow kidney disease progression, and possess senolytic properties.
SGLT-2 inhibitors may be beneficial for patients with diabetes and related complications.
Supports 2025New - Metabolic adaptationStrong
GC ablation in mice fed a high fat diet protects against obesity and type 2 diabetes.
This suggests that targeting GC could be beneficial in preventing obesity in high-fat diet scenarios.
Supports 2026New - Metabolic adaptationStrong
Adjustment for covariates differing between trial type and associated with BW reduction nullified the association between T2D status and weight loss (p = 0.93).
This suggests that addressing demographic and comorbid factors may improve weight loss outcomes in T2D patients.
Refutes 2026New - Metabolic adaptationStrong
No significant differences in metabolic flexibility were observed between the RE+CON and RE+PRO groups.
Combining resistance exercise with either a control or high protein diet does not significantly alter metabolic flexibility outcomes.
Refutes 2026New - Metabolic adaptationStrong
MetFlex to fat showed no correlation to MetFlex measured during the clamp.
Different methods may yield different insights into metabolic flexibility.
Refutes 2025New - Metabolic adaptationGood
After 6 months of semaglutide treatment, participants showed significant reductions in Psoriasis Area and Severity Index (PASI) by 48%, body mass index (BMI), and preperitoneal and superficial fat.
Semaglutide may be an effective treatment for improving psoriasis severity in obese patients.
Supports 2025New - Metabolic adaptationGood
Lifestyle modifications remain the primary approach to managing MASLD, but their effectiveness is often limited.
Practitioners should be aware of the limitations of lifestyle modifications in MASLD management.
Qualifies 2025New - Metabolic adaptationGood
A higher proportion of carbohydrate intake is associated with an increased risk of cardiovascular disease and all-cause mortality in Japanese people with type 2 diabetes.
Practitioners should consider the carbohydrate intake levels of patients with type 2 diabetes when assessing cardiovascular risk.
Supports 2025New - Metabolic adaptationGood
The mean total low-carbohydrate diet score and animal low-carbohydrate diet score are inversely associated with the incidence of cardiovascular events and all-cause mortality.
Encouraging low-carbohydrate dietary patterns may benefit patients with type 2 diabetes in reducing cardiovascular risk.
Supports 2025New - Metabolic adaptationLimited
A Mediterranean diet is advised for all MASLD patients, with a target of 7-10% weight loss for those with excess weight.
Practitioners should recommend a Mediterranean diet and aim for weight loss in MASLD patients with excess weight.
Supports 2025New